Nonetheless, considering the pathological complexity of sepsis, we do not think that measuring a specific WARS1 level at a given point would work as a sole determinant to stratify the patients who would respond to the anti-WARS1 MAb treatment. The gene discussed is WARS1; the disease is Sepsis.